Although BTK inhibitors are receiving substantial attention as novel DMTs for MS, the results of ongoing phase III trials will be pivotal in evaluating whether the BTK inhibitors described demonstrate the desired benefit–risk profiles. Here, BTK is linked to myeloid sarcoma.